📰 Nasdaq Pcvx News
Page 7 - Nasdaq Pcvx News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Pcvx. Real-time updates on events, politics, business and more.
January 20, 2023
Mid-cap stocks are proving to be an attractive investment option over the past few years. In fact, the S&P MidCap 400 index has performed better t
November 15, 2022
Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses. In recent years, mid-cap stocks have o
October 23, 2022
SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
May 24, 2022
Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) VP Jeff Fairman sold 4,112 shares of Vaxcyte stock in a transaction on Friday, May 20th. The stock was sold at an average price of $25.50, for a total transaction of $104,856.00. Following the transaction, the vice president now directly owns 321,227 shares in the company, valued at $8,191,288.50. […]
May 10, 2022
Vaxcyte (NASDAQ:PCVX – Get Rating) issued its earnings results on Monday. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.05), MarketWatch Earnings reports. Shares of NASDAQ PCVX traded up $0.04 during midday trading on Tuesday, hitting $21.45. 27,829 shares of the stock traded hands, compared to […]
April 10, 2022
Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) VP Jeff Fairman sold 5,000 shares of the business’s stock in a transaction on Tuesday, April 5th. The shares were sold at an average price of $25.59, for a total value of $127,950.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is […]
April 7, 2022
Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $25.68, but opened at $26.55. Vaxcyte shares last traded at $26.38, with a volume of 1,109 shares traded. Several research firms have recently commented on PCVX. Zacks Investment Research downgraded shares of […]
March 14, 2022
Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) SVP Paul Sauer sold 6,000 shares of Vaxcyte stock in a transaction dated Thursday, March 10th. The shares were sold at an average price of $25.00, for a total value of $150,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be […]
March 4, 2022
Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) – Equities researchers at Jefferies Financial Group lowered their FY2022 earnings estimates for shares of Vaxcyte in a report issued on Monday, February 28th. Jefferies Financial Group analyst R. Song now forecasts that the company will post earnings per share of ($2.38) for the year, down from their previous […]
October 28, 2021
FOSTER CITY, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health...